Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

BACKGROUND: Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on long-term H treatment of patients. The Rollover Protocol (ROP) Study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Volkmar, Clemens, Michael, Jassem, Jacek, Al-Sakaff, Nedal, Auclair, Petra, Nüesch, Eveline, Holloway, Debbie, Shing, Mona, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856394/
https://www.ncbi.nlm.nih.gov/pubmed/29544445
http://dx.doi.org/10.1186/s12885-018-4183-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856394/
https://www.ncbi.nlm.nih.gov/pubmed/29544445
http://dx.doi.org/10.1186/s12885-018-4183-2

Ejemplares similares